MedPath

Analysis of Remote-ischemic Preconditioning Effects on Kidney Function

Completed
Conditions
Renal Function
Renal Injury
Interventions
Procedure: remote ischemic preconditioning
Registration Number
NCT01925235
Lead Sponsor
University of Cologne
Brief Summary

Patients with impaired renal function are at elevated risk for development of acute kidney injury (AKI). AKI is associated with increased risk for cardiovascular morbidity and mortality. Effective AKI prevention strategies are needed. Remote ischemic preconditioning (RIPC) is a novel and successful strategy to attenuate contrast medium induced AKI in patients undergoing elective coronary angiography.

The retrospective RenPro-TAVI Trial was designed to test the hypothesis whether remote ischemic preconditioning might attenuate kidney injury in patients receiving transcatheter aortic valve implantation (TAVI).

Patients with impaired renal function undergoing TAVI will be evaluated in respect whether they received remote ischemic preconditioning before the procedure or not. This study will give insight if RIPC might be beneficial in these patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria
  • age >= 18 years
  • impaired renal function (baseline eGFR of <60 ml/min)
  • high INTEGER risk score > 11
  • high EuroSCORE (European system for cardiac operative risk evaluation)
Exclusion Criteria
  • severe renal impairment (eGFR <15 ml/min and/or in chronic dialysis)
  • recent (<=30 days) contrast media exposure
  • patients enrolled in concomitant studies
  • fertile women

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
RIPCremote ischemic preconditioningpatients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
Primary Outcome Measures
NameTimeMethod
change in parameters determining renal function and injury48 hours after TAVI

serum creatinine, cystatin c, urinary neutrophil gelatinase-associated lipocalin (NGAL)

Secondary Outcome Measures
NameTimeMethod
acute kidney injury48 hours after TAVI

increase in serum creatinine ≥25% or ≥0.5 mg/dL above baseline at 48 hours after TAVI

Trial Locations

Locations (1)

University Hospital of Cologne

🇩🇪

Cologne, NRW, Germany

© Copyright 2025. All Rights Reserved by MedPath